poractant alfa

poractant alfa

 [por-ak´tant al´fah]
an extract of porcine lung surfactant administered by instillation via the endotracheal tube in treatment of respiratory distress syndrome of the newborn.

poractant alfa

/por·ac·tant al·fa/ (por-ak´tant al´fah) an extract of porcine lung surfactant used in the treatment of respiratory distress syndrome of the newborn.

poractant alfa

a lung surfactant extract.
indication It is used in the treatment (rescue) of respiratory distress syndrome in premature infants.
contraindication None is currently known.
adverse effects Concurrent illnesses that have occurred during treatment with this drug include pulmonary air leaks, pulmonary interstitial emphysema, apnea, pulmonary hemorrhage, patent ductus arteriosus, intracranial hemorrhage, severe intracranial hemorrhage, necrotizing enterocolitis, posttreatment sepsis, and posttreatment infection. Adverse effects include bradycardia, oxygen desaturation, pallor, vasoconstriction, hypotension, and hypertension.
References in periodicals archive ?
Czesc 1 Ceftazidime 0,25 g, Cisatracurium besylate 10 mg/5 ml i 5 mg/2,5 ml, Mivacurium 10 mg/5 ml i 20 mg/10 ml, Czesc 2 Poractant Alfa 120 mg/1,5 ml, Czesc 3 Lamivudine syrop 10 mg/ml 240 ml ,Lamivudine tabl.
Antibiotics and chemotherapeutics for dermatological use
Compliations among premature neonates treated with beractant and poractant alfa.
A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome.
The importance of administration of early surfactant and nasal continuous positive airway pressure in newborns with respiratory distress syndrome
On the other hand, poractant alfa patients had a lower overall mortality (14 of 99 [14%; 95% CI, 8% to 23%]) than the most recent large multicentered trials (442 of 2,168 [20%; 95% CI, 17% to 23%]).
Yet it seems likely that unknown, uncontrollable, unpredictable factors generated a situation in which pumactant performed much more poorly than in previous studies and poractant alfa much better.
The marketers of Curosurf (Chiesi Farmaceutici SpA in the European Union and Dey Laboratories, LP in the USA) have sponsored a series of small clinical trials that have compared the acute response of patients to prophylactic treatment at birth with poractant alfa or beractant.
25% for poractant alfa, while those for beractant (8.
Is there evidence for a mortality difference between exogenous surfactant preparations in neonatal RDS?
Poractant alfa (Curosurf) for respiratory distress syndrome.
Pediatric Labeling of Psychiatric Drugs
A randomized, multicenter masked comparison trial of poractant alfa (Curosurf ) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants.
Complications among premature neonates treated with beractant and poractant alfa.
The use of surfactant in the neonatal period- the known aspects, those still under research and those which need to be investigated further
Examples of natural surfactant include Beractant (Survanta), Poractant Alfa (Curosurf), and Clafactant (Infasurf)
Poractant alfa is a natural surfactant obtained as an extract of porcine lung.
Surfactant: agents utilized to lower surface tension
Medical browser ?
Full browser ?